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1. Introduction 
Pyrrolidine, thiazole and indole ring systems are important 
structural skeletons found in the structures of various alkaloids, 
natural compounds, pharmaceuticals, drugs and many other 
bioactive molecules.1,2,3,4 The pyrrolidine ring is present in many 
bioactive compounds and it is useful as building block for the 
construction of some other biologically important 
heterocycles.5,6,7,8 Various chemo-, regio-, and enantioselective 
reactions, and some versatile tactical combination of the 
pyrrolidine ring have been reported by us and others.5,9,10,11,12,13 
Hetereocycles bearing thiazole moieties have been extensively 
studied and reviewed finding a large series of families showing 
potent bioactivities such as antibiotic, antimycobacterial, 
anticancer and AchE inhibitory activities.14,15,16,17,18,19,20 In 
addition, it is well known that indole skeleton, integrated in 
natural compound or as part of synthetic molecules, has 
displayed versatile pharmacological properties such as 
anticancer,21 antiviral,22 anticonvulsant23 cardiovascular, 24 
antidiabetic, antimalarial, antibacterial, anti-inflammatory 
antifungal activities.25,26,27  
Various compounds containing pyrrolidine and thiazole ring 
system have been found to be antibacterial agents as structures 
1,1 and phosphatidylinositol-3-kinase alpha (PI3Ka) inhibitors 2 
and 3. 28,29 Also, general (pyrrolidin-1-yl)thiazole structures 4, 
prepared from racemic or D- or L-proline or trans-4-hydroxy-L-
proline, have been employed for the treatment and/or prevention 
of KAT (kynurenine aminotransferase) II-associated disorders,30 
as drugs with good antiproliferative activity and epidermal 
growth factor receptor tyrosine kinase (EGFR-TK) inhibitory 
activity,31and as β3-adrenergic receptor agonists.32 
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A versatile, facile and concise approach to access to highly substituted functionalized 2-
(pyrrolidin-1-yl)thiazole ring system is accomplished. The efficient protocol proceeds by the 
reaction of corresponding racemic or enantiomerically enriched pyrrolidines and readily 
available benzoylisothiocyanate in acetonitrile followed by sequential reaction of readily 
available alpha-bromo ketones in acetone. The selectivity and good yield in the desired product 
is another important advantage of this reaction protocol. In a few cases, the resulting N-
benzoylthiourea intermediate cyclizes spontaneously before reacting with the benzophenone 
component. Finally, a wide study of the biological scope of this new bisheterocyclic molecules 
is reported.  
2017 Elsevier Ltd. All rights reserved.
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Figure 1. Several biologically important 2-(pyrrolidin-1-
yl)thiazole skeletons. 
 
As a continuation of our work regarding the synthesis of 
aroylaminocarbo-N-thioylpyrrolidine 7, their participation in the 
formation of several metal complexes,11,33,34 and the synthesis of 
thiohydantoin derivatives 8 (Scheme 1),35 we consider that the 
combination of both polysubstituted pyrrolidines and thiazole 
into a new highly functionalized 2-(pyrrolidin-1-yl)thiazole 
frameworks would be very attractive.   
 
 
Scheme 1. Synthesis of benzoylaminocarbo-N-thioylpyrrolidine 
and thiohydantoin derivatives from polysusbstituted prolinates 6. 
 
 In this article, we report the synthesis of molecules bearing 
polysubstituted pyrrolidine-thiazole heterocycles from readily 
available starting materials. In many cases, the incorporation of 
another heterocyclic system such as indole resulted to be 
beneficial since the biological point of view. Their antibacterial 
activity against a range of Gram-positive and Gram-negative 
bacteria and their antimycobacterial activity against M. 
tuberculosis H37Rv strain were also tested. 
 
2. Results and Discussion 
For the synthesis of 2-(pyrrolidin-1-yl)thiazoles 5 the 
polysubstituted pyrrolidines 6 were allowed to react with N-
benzoyl isothiocyanate affording intermediate 
benzoylaminocarbo-N-thioylpyrrolidines 7,35 which was 
transformed into the corresponding heterocycles 5 with α-
bromobenzophenones in refluxing acetone.36 
 
 Scheme 2. General synthetic design for the preparation of 5. 
Firstly, we employed enantiomerically enriched prolinate 
derivatives with the aim to obtain reliable biological data for each 
enantiomer. Thus, prolinates 6a-i (Figure 2), prepared in in 
different er (see experimental part), through a catalytic 
enantioselective 1,3-DC according to the published procedures in 
very high enantiomeric ratio (see experimental part), were 
submitted to the addition reaction onto N-benzoyl isothiocyanate 
in dry acetonitrile at room temperature for 24 h affording 
benzoylaminocarbo-N-thioylpyrrolidines 7 in almost quantitative 
yields. Without any other purification these intermediate products 
7 were immediately (in order to prevent spontaneous 
cyclizations) allowed to react with 2-bromo-4′-
methoxyacetophenone in refluxing acetone for 48 h (Scheme 3 
and Table 1).     
 
 
Figure 2. Enantiomerically enriched pyrrolidines 6 employed in 
the synthesis of 2-(pyrrolidin-1-yl)thiazoles 5. 
 
The behavior of all starting prolinate derivatives 6 (Figure 2) 
was not predictable. For example, N-Methylmaleimide (NMM) 
derivatives bearing a substituent in R1 (different to hydrogen) 
afforded the desired thiazoles in good overall yields (Table 1, 
entries 2 and 3). However, in the reaction of 6a (R1 = H, Ar1 = 
Ph) the cyclization of the intermediate (non-isolated) 
benzoylaminocarbo-N-thioylpyrrolidine 7a occurred rapidly 
furnishing N-benzoylthiohydantoin N-Bz-8a in 81% yield (Table 
1, entry 1). Enantiomerically enriched prolinates 6d-6h afforded 
their corresponding products 5 or 5’ in moderate to good yields 
(Table 1, entries 4-8). In a couple of examples we detected the 
unexpected hydrolysis of the tert-butyl ester (compound 5g’) and 
the methyl ester (compound 5h’) under this reflux of wet acetone 
obtaining in these two examples the lowest yields of this series. 
Another example of fast cyclization occurred during the reaction 
of the highly substituted nitroprolinate 6i which afforded the N-
debenzoylated thiohydantoin 8i in excellent 95% yield (Table 1, 
entry 9). In all these examples the absolute configuration was 
retained. 
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Scheme 3. Two-step process to access enantiomerically enriched 
heterocycles 5. 
 
Table 1. Synthesis of enantiomerically enriched 2-(pyrrolidin-1-
yl)thiazoles 5 
Entry 6 Product  No. Yield (%)a 
1 6a 
  
N-Bz-8a 81 
2 6b 
 
5b 60 
3 6c 
  
5c 62 
4 6d 
 
5d 68 
5 6e 
 
5e 82 
6 6f 
 
5f 64 
7 6g 
 
5g’ 43 
8 6h 
   
5h’ 34 
9 6i 
 
8i 95 
a
 Isolated combined yield from cycloadducts 6 after flash 
chromatography. 
 
 
 
This series of 2-(pyrrolidin-1-yl)thiazoles 5 resulted to be 
time- and temperature sensitive and after two days storage at 25 
ºC large decompositions were detected. According to previous 
results and tests, the combination of a suitable dipolarophile 
together with the introduction of a (3-indolyl)methyl, phenyl or 
benzyl substituent as R1 in molecules 6 (Scheme 3) would ensure 
a high stability of the resulting both benzoylaminocarbo-N-
thioylpyrrolidines 7 and thiazoles 5. It is known, for example, 
that it was not an easy task to cyclize the corresponding indolyl 
derivatives to thiohydantoins 8,34 but when we tried to synthesize 
the optically pure compound 6j37 the corresponding enantiomeric 
ratio was very poor. 
Next, the preparation of several selected racemic 
cycloadducts (which could not be obtained as enantiomerically 
pure form) 6j-6o depicted in Figure 3 was carried out via thermal 
or metal-catalyzed 1,3-DC (see experimental part) and, 
immediately, they were submitted to the reaction with 
benzoylisothiocyanate affording benzoylaminocarbo-N-
thioylpyrrolidines 7. These compounds 7, obtained in very good 
yields (80-92%, Table 2, entries 1-6) were stable and could be 
purified by flash chromatography detecting the appearance of 
rotamers in several samples. Analogously, the stability of the 
racemic thiazole derivatives was also appropriate to study their 
biological properties. Upon reaction of 7 with 2-bromo-4′-
methoxyacetophenone for 24-48 h in refluxing acetone, 2-
(pyrrolidin-1-yl)thiazoles 5j-o were generated in 65-83 yields 
(Table 2, entries 1-6). 
   
 
Figure 3. Racemic endo-pyrrolidines 6 employed in the synthesis 
of 2-(pyrrolidin-1-yl)thiazoles 5. 
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Scheme 3. Synthesis of racemic benzoylaminocarbo-N-
thioylpyrrolidines 7 and thiazoles 5. 
 
Table 2. Synthesis of enantiomerically enriched 2-(pyrrolidin-1-
yl)thiazoles 5 
Ent. 6 Product 7, Yield (%)a Product 5, Yield (%)a 
1 6j 
 
7j, 86%   5j, 65% 
2 6k 
7k, 85 
 5k, 
82% 
3 6l 
 
7l, 80   5l, 76% 
4 6m 
 
7m, 89 
  
5m, 83% 
5 6n 
 
7n, 92% 
  
5n, 70% 
6 6o 
 
7o, 80 
  
5o, 75% 
a
 Isolated combined yield from after flash chromatography. Ar2 = 
4-(MeO)C6H4. 
 
The thiazole synthesis was very sensitive to the protic 
character of the solvent employed. Thus, when anhydrous 
methanol was used instead of acetone 2,3-disubstituted thiazoles 
9n and 9o were generated in 72 and 83 % yield, respectively, as 
consequence of a previous debenzoylation of the starting 
compound 6n or 6o and subsequent nucleophilic attack of the 
sulfur atom followed by cyclization (Scheme 4).  
 
 
Scheme 4. Synthesis of racemic thiazoles 9n and 9o. 
 
Anti-tuberculosis (TB) activity: Anti-TB activity of the 
tested compounds was performed according to literature method 
utilizing Microplate Alamar Blue assay.38 The compounds 6m,j,l, 
7l,m,n, 5m,k,l and 9o were screened against M. tuberculosis 
H37Rv strain and measured by means of MIC values (µg/cm3). 
Ethambutol (EMB) (Sigma E4630) and isoniazid (INH) (Sigma 
I3377) were used as standard reference drugs. The activity of the 
tested compounds (Table 3), showed moderate to good activity, 
in the range of 3.90-62.5 µg/ml3 when compared to isoniazid and 
ethambutol as known active reference drugs. In some cases better 
activity than known reference ethambutol. The compounds 
7k,l,m revealed the highest activities with the MIC values 3,90-
7.81  µg/ml whereas the compound 6j showed a moderate 
activity value of 20 µg/mL and  6f and 7n showed a moderate 
activity values 31.25 µg/ml and the others compounds showed 
the lowest activities with the MIC values 62.5 µg/ml. Chiral 
compounds 5b-h’ were not tested due to their instability. 
Although the mode of action or biological target of these 
molecules is unknown at the moment. 
The indicated target compounds in the Table 3 inhibited the 
growth of bacteria at minimum inhibitory concentrations (MIC) 
values in the range of 62.5 -500 µg/ml. The control, ampicillin, 
showed activity against the tested bacterıa with a range of 125-
0.9 µg/mL.of MIC values. 
 
Antibacterial Activity: Stock solutions were prepared by 
dissolving the tested compounds in DMSO and then diluting in 
Mueller-Hinton broth and Triptic soy broth and the test medium 
were prepared at concentrations of 500, 250, 125, 62.5, 31.25, 
15.62, 7.8, 3.9 and 1.9 µg mL-1.  The minimum inhibitory 
concentrations (MIC) values was determined by agar dilution in 
duplicate as recommended by the Clinical Laboratory Standards 
Institute39  To ensure that the solvents had no effect on microbial 
growth, a control test was performed containing inoculated broth 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5 
supplemented with DMSO at the same dilutions used for the test 
compounds and was determined to be inactive. The minimum 
inhibitory concentrations (MIC) for each compound were 
investigated against standard bacterial strains: Staphylococcus 
aureus (ATCC 25925), Escherichia coli (ATCC 25923), 
Acinetobacter baumanii (ATCC 02026), Bacillus subtilis (ATCC 
6633) and Aeromonashydrophila (ATCC 95080) obtained from 
the Refik Saydam Hıfzısıhha Institute, Ankara, Turkey. 
Ampicillin was used as control drug. The observed data on the 
antibacterial activity of the compounds and the control drug are 
given in Table 3.  
 
3. Conclusions 
Two different types of thiazole derivatives can be obtained 
depending on the solvent employed. It was not predictable the 
behavior of benzoylaminocarbo-N-thioylpyrrolidines because the 
spontaneous cyclization cannot be controlled at all. The nature of 
this process is strongly dependent of the substituents at 2, 3 and 
4-positions of the prolinate. The screened compounds showed 
moderate antibacterial activity against various bacteria strains, in 
addition showed good anti-TB activity against M. tuberculosis 
H37Rv strain, the target compounds showed better activity than 
the antibacterial results but moderate activity when compared to 
isoniazid and ethambutol as known reference drugs (Table 1). It 
is remarkable that the highst activity corresonded to 6o, 7o and 
9o, which posses p-chlorophenyl-methoxycarbonyl-[3-
indolylmehyl] common substituents around pyrrolidine nucleus. 
Further research regarding the incorporation of these type 
compounds to another scaffolds ıs under investigation and their 
biological activity will be reported in due course. 
 
4. Experimental Section 
4.1. General information 
Melting points were determined on a Kofler hot stage 
apparatus and are uncorrected. Mass spectra were recorded at 70 
eV on a VG Autospec mass spectrometer. Nuclear magnetic 
resonance spectra and decoupling experiments were determined 
at 250 MHz on a Q.E 300 instrument, at 300 MHz on a Bruker 
Avance AC-300 and at 500 MHz on a Bruker AM500 
spectrometer as specified. Chemical shifts are given in parts per 
million (δ) downfield from tetramethylsilane as internal standard. 
Spectra were determined in CDCl3 except where otherwise 
stated. The structurally most important peaks of the IR spectra 
(recorded using a Nicolet 510 P-FT-ATR) are listed and 
wavenumbers are given in cm-1. Flash column chromatography 
was performed using silica gel 60 (230-400 mesh). Kieselgel 
columns were packed with silica gel GF254 (Merck 7730). 
Petroleum ether refers the fraction with bp 40-60 ºC unless 
otherwise specified. Specific optical rotations were measured in a 
JASCO polarimeter 2000-series. HPLC analysis was performed 
employing chiral stationary phase columns in a JASCO 2000 
series. Microanalyses were obtained using a Carlo-Erba Model 
1106 instrument. Chiral compounds 6a (99:1 er),39 6b (96:4 er),39 
6c (99:1 ee),39 6d (85:15 er),40 6e (85:15 er),40 6f (91:9 er), 6g 
(75:25 er),40 6h (99%, ee),41 6i (99% ee),41 were prepared 
according to published procedures. The known racemic 
pyrrolidines and N-aminocarbothiolpyrrolidines 6j,42,43 6m,35 
6n,34 7m35 were prepared according to published procedures. 
Novel compounds were prepared by following the general 
procedures given below. 
 
4.2. Synthetic procedures and characterization data 
4.2.1. General procedure for the synthesis of enantiomerically 
enriched compounds 5b-f, 5g’, 5h’, N-Bz-8a and 8i. 
In a flask containing the corresponding prolinate 6a-i (0.5 
mmol) in dry acetonitrile (10 mL) N-benzoylisothiocyanate (64 
µL, 0.5 mmol) was added and the resulting solution was stirred 
under reflux for 24 h. The solvent was evaporated and the crude 
mixture was analysed by 1H NMR. At this point the presence of 
compounds N-Bz-8a and 8i was observed. For the other 
examples, the crude compound was immediately dissolved in dry 
acetone (10 mL) containing 2-bromo-4′-methoxyacetophenone 
(115 mg, 0.5 mmol) and the mixture refluxed for 48 h. The 
solvent was evaporated under reduced pressure to give a sticky 
oil which was purified by column chromatography (flash silica) 
obtaining compounds 5 or 5’. 
4.2.1.1. (5R,5aS,8aR,8bS)-2-benzoyl-7-methyl-5-phenyl-3-
thioxohexa-hydropyrrolo[3',4':3,4]pyrrolo[1,2-c]imidazole-
1,6,8(7H)-trione: (N-Bz-8a). White solid (169.9 mg, 81 % yield); 
mp 205-209 ºC; [α] = -3.3 (c 1, DMSO, 99:1 er); IR υmax: 3343, 
1745, 1702, 1530 cm-1; 1H NMR (300 MHz, DMSO) δ: 7.15-7.65 
(m, 10H, ArH), 5.81 (d, J = 10.4 Hz, 1H), 5.25 (d, J = 10.1 Hz, 
1H), 4.08-4.33 (m, 2H), 3.72 (s, 3H, NCH3); 13C NMR (DMSO) 
δ: 181.4, 174.5, 173.0, 168.3, 164.7, 136.8 (ArC), 132.7, 132.3, 
128.2, 128.1, 127.9, 127.8, 127.3, 99.5, 52.2 (CH), 49.9 (CH), 
46.2 (CH), 40.7 (CH), 24.1 (CH3); MS (EI): m/z 288 (M+- 
C8H3O2, 12%), 230 (15), 229 (96), 178 (11), 177 (96), 167 (16), 
149 (45), 146 (19), 145 (22), 144 (65), 143 (17), 142 (10), 118 
(15), 117 (100), 116 (12), 115 (25), 112 (11), 105 (43), 91 (13), 
90 (13), 84 (53), 83 (11), 77 (26), 71 (16), 70 (14), 66 (58), 57 
(25), 55 (15), 51 (11), 44 (34), 43 (43), 41 (12); HRMS (DIP): 
m/z calculated for C22H17N3O4S: 419.0940, found: 419.0961. 
4.2.1.2. Methyl (1S,3R,3aS,6aR)-1-isobutyl-2-(5-(4-
methoxybenzoyl)-4-phenylthiazol-2-yl)-5-methyl-4,6-dioxo-3-
phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (5b): 
Yellow oil (191.2 mg, 60 % yield); [α] = 26.3 (c 0.8, CDCl3, 
96:4 er
 
); IR υmax: 2954, 1741, 1708, 1596, 1508 cm-1; 1H NMR 
(300 MHz, CDCl3) δ: 7.31-7.68 (m, 6H), 7.25-7.3 (m, 3H), 6.99-
7.16 (m, 3H), 6.55 (d, J = 8.9 Hz, 2H), 5.27 (d, J = 10.8 Hz, 1H), 
4.10 (dd, J = 10.8, 9.1 Hz, 1H), 3.88 (s, 3H, OCH3), 3.71 (s, 3H, 
OCH3), 3.58 (d, J = 9.1 Hz, 1H), 3.07 (dd, J = 15.1, 7.4 Hz, 1H), 
2.69 (s, 3H, NCH3), 2.22 (dd, J = 15.1, 3.5 Hz, 1H), 1.64 (m, 
1H), 1.06 (d, J = 6.7 Hz, 3H, CH3), 0.77 (d, J = 6.6 Hz, 3H, 
CH3); 13C NMR (CDCl3) δ: 187.7, 174.5, 173.1, 171.1, 164.9 
(ArC), 162.7, 155.6, 135.2, 134.7, 131.9, 130.0, 129.0, 128.5, 
127.7, 124.6, 113.1, 75, 68.9 (CH), 55.4 (CH3), 54.4 (CH3), 53.0 
(CH), 50.9 (CH), 42.7 (CH2), 25.9 (CH3), 24.9 (CH3), 24.1 (CH3), 
23.7 CH); MS (EI): m/z 637 (M+, <2%), 582 (26), 581 (69), 578 
(14), 549 (15), 522 (27), 399 (15), 385 (11), 135 (100), 133 (11), 
77 (12); HRMS (DIP): m/z calculated for C36H35N3O6S: 
637.2242, found: 637.2239. 
4.2.1.3. Methyl (1S,3R,3aS,6aR)-1-benzyl-2-(5-(4-
methoxybenzoyl)-4-phenylthiazol-2-yl)-5-methyl-4,6-dioxo-3-
phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (5c): 
Yellow oil (208.2 mg, 62 % yield); [α] = 66.0 (c 0.6, CDCl3, 
99:1 er); IR υmax: 2951, 1744, 1703, 1597 cm-1; 1H NMR (300 
MHz, CDCl3) δ  mixed rotamers: 7.48 (d, J = 6.0 Hz, 4H, ArH), 
7.33 (m, 10H, ArH), 7.10 (m, 18H, ArH), 6.57 (d, J = 6.0 Hz, 
4H, ArH), 4.86 (d, J = 6.0 Hz, 1H, major rotamer), 4.59 (d, J = 
12 Hz, minor rotamer), 4.54 (d, J = 9.0 Hz, 1H, major rotamer), 
4.00 (s, 6H, both rotamers), 3.89 (s, 3H, minor rotamer), 3.72 (s, 
3H, major rotamer), 3.66 (d, J = 6.0 Hz, 1H minor rotamer), 3.52 
(dd, J = 6.0, 6.0 Hz, minor rotamer), 3.49 (d, J = 12.0 Hz, minor 
rotamer), 3.44 (d, J = 6.0 Hz, 1H, major rotamer), 3.37 (d, J = 9.0 
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Hz, 1H, major rotamer), 3.10 (d, J = 12.0 Hz, 1H, minor 
rotamer), 2.79 (s, 3H, major rotamer), 2.66 (dd, J = 9.0, 6.0 Hz, 
1H, mayor rotamer), 2.60 (s, 3H, minor rotamer); 13C NMR 
(CDCl3): δ  mixed rotamers: 187.8 (CO), 175.6 (ArC and CO), 
174.6, 174.3, 173.2, 171.3, 170.2, 165.1, 162.8, 155.9, 135.8, 
135.0, 134.6, 132.0, 130.4, 130.3, 130.1, 129.7, 129.4, 129.3, 
129.1, 128.7, 128.6, 128.1, 127.7, 127,3, 125.6, 124.9, 113.2, 
75.4 (C), 71.3, 69.1 (CH), 61.4, 55.5 (ArOMe), 55.3, 54.2 
(CO2Me), 53.8, 53.1 (CH), 52.5, 49.9 (CH), 49.5, 40.4 (CH2), 
39.2, 24.9 (CH3), 24.6;  MS (EI): m/z 671 (M+, 16%), 582 (12), 
581 (36), 580 (100), 464 (10), 463 (32), 437 (10), 399 (21), 135 
(95), 115 (13), 91 (20), 77 (13); HRMS (DIP): m/z calculated for 
C39H33N3O6S: 671.2090, found: 671.2086.  
4.2.1.4. Trimethyl (2S,3R,4S,5R)-1-(5-(4-methoxybenzoyl)-4-
phenylthiazol-2-yl)-5-phenylpyrrolidine-2,3,4-tricarboxylate 
(5d): Yellow oil (209.0 mg, 68 % yield); [α]	 = 12.4 (c 1, 
CDCl3, 85:15 er); IR υmax: 2952, 1737, 1596, 1509, 1473 cm-1; 1H 
NMR (300 MHz, CDCl3) δ: 7.41-7.54 (m, 4H, ArH), 7.22-7.37 
(m, 5H, ArH), 6.99-7.14 (m, 3H, ArH), 6.54 (d, J = 9.0 Hz, 2H, 
ArH), 5.63 (d, J = 8.3 Hz, 1H), 5.05 (d, J = 6.8 Hz, 1H), 3.89 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.64-3.77 
(m, 2H), 3.18 (s, 3H, OCH3); 13C NMR (CDCl3) δ: 187.7 (C), 
169.9 (C), 169.4 (C), 168.4 (C), 162.6 (ArC), 156.0, 134.6, 
134.0, 131.8, 131.6, 130.2, 130.0, 129.3, 128.7, 128.6, 127.8, 
127.7, 127.5, 124.8, 113.0, 68.46 (CH), 63.6 (CH), 55.4 (CH3), 
52.7 (CH3), 52.4 (CH3), 51.6 (CH3), 51.2 (CH), 47.7 (CH); MS 
(EI): m/z 615 (M++ H+, 16%), 614 (42), 556 (16), 555 (44), 463 
(15), 412 (14), 411 (52), 393 (18), 135 (100), 133 (12), 121 (11), 
115 (11), 77 (16); HRMS (DIP): m/z calculated for C33H30N2O8S: 
614.1723, found: 614.1719.  
4.2.1.5. Trimethyl (2S,3R,4S,5R)-5-(4-chlorophenyl)-1-(5-(4-
methoxybenzoyl)-4-phenylthiazol-2-yl)pyrrolidine-2,3,4-
tricarboxylate (5e): Yellow oil (266.2mg, 82 % yield); [α] = -
2.3 (c 1, CDCl3, 85:15 er); IR υmax: 2951, 1741, 1596, 1508 cm-1; 
1H NMR (300 MHz, CDCl3) δ: 7.42-7.50 (m, 3H, ArH), 7.32-
7.38 (m, 2H, ArH), 7.22-7.30 (m, 3H, ArH), 7.02-7.17 (m, 3H, 
ArH), 6.56 (d, J = 8.8 Hz, 2H, ArH), 5.60 (d, J = 7.9 Hz, 1H), 
5.08 (d, J = 6.6 Hz, 1H), 3.89 (s, 3H, OCH3), 3.7 (s, 3H, OCH3), 
3.71 (s, 3H, OCH3), 3.65-3.76 (m, 2H), 3.26 (s, 3H, OCH3); 13C 
NMR (CDCl3) δ: 187.5 (C), 169.8 (C), 169.2 (C), 168.3 (C), 
168.1 (ArC), 162.8, 134.6, 134.0, 132.8, 131.9, 130.1, 130.0, 
129.4, 128.9, 128.8, 127.8, 124.8, 113.1, 67.8 (CH), 64.0 (CH), 
55.4 (CH3), 52.9 (CH3), 52.5 (CH3), 51.8 (CH3), 51.0 (CH), 47.9 
(CH); MS (EI): m/z 650 (M++ H+, 12%), 649 (11), 648 (27), 591 
(11), 589 (26), 447 (16), 446 (12), 445 (41), 393 (18), 135 (100), 
77 (11); HRMS (DIP): m/z calculated for C33H29ClN2O8S: 
648.1333, found: 648.1348.  
4.2.1.6. (2S,3S,4R,5S)-1-(5-(4-Methoxybenzoyl)-4-
phenylthiazol-2-yl)-4-nitro-3,5-diphenylpyrrolidine-2-carboxylic 
acid (5f): Yellow oil (196.7 mg, 64% yield); [α]
 = 47.5 (c 0.7, 
CDCl3, 91:9 er); IR υmax: 2929, 2852, 1740, 1597, 1510 cm-1; 1H 
NMR (300 MHz, CDCl3) δ: 7.04-7.64 (m, 12 H, ArH), 6.54 (d, J 
= 8.9 Hz, 2H, ArH), 5.18 (d, J = 7.3 Hz, 1H), 5.01 (d, J = 8.1 Hz, 
1H), 4.02-4.05 (m, 2H), 3.94 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 
3.71 (s, 3H, OCH3), 3.32 (s, 3H, OCH3); 13C NMR (CDCl3) δ: 
187.6 (C), 170.9 (C), 170.5 (C), 168.8 (C), 166.6 (ArC), 162.8, 
135.2, 134.0, 131.9, 130.2, 129.2, 129.0, 128.8, 128.3, 128.1, 
127.8, 124.7, 113.2, 100.13, 67.8 (CH), 65.3 (CH), 55.5 (CH3), 
53.2 (CH3), 53.1 (CH3), 52.4 (CH3), 52.2 (CH), 48.0 (CH); MS 
(EI): m/z 615 (M+ + H+, 15%), 614 (43), 555 (23), 495 (28), 464 
(12), 463 (37), 411 (34), 393 (28), 135 (100), 133 (13), 77 (15); 
HRMS (DIP): calculated for (C33H30N2O8S): 614.1723, found, 
614.1729.  
4.2.1.7. (2R,3S,5S)-1-(5-(4-methoxybenzoyl)-4-phenylthiazol-
2-yl)-5-(methoxycarbonyl)-2-phenylpyrrolidine-3-carboxylic acid 
(5g’): Yellow oil (116.7 mg, 43% yield); [α] = -37.5 (c 0.6, 
CDCl3, 75:25 er); IR υmax: 2948, 1743, 1597, 1510 cm-1; 1H NMR 
(300 MHz, CDCl3) δ: 6.81-7.87 (m, 12H, ArH), 6.54 (d, J = 9 
Hz, 2H, ArH), 5.12 (d, J = 8.9 Hz, 1H), 4.78 (dd, J = 10.2, 6.7 
Hz, 1H), 3.89 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.62-3.77 (m, 
1H), 2.75 (m, 1H), 2.55 (dt, J = 13.1, 6.7 Hz, 1H); 13C NMR 
(CDCl3) δ: 187.7 (C), 172.54 (C), 171.8 (C), 167.0 (ArC), 162.8, 
155.3, 135.4, 133.8, 132.5, 131.9, 130.2, 130.1, 129.0, 128.9, 
128.8, 128.2, 127.8, 127.5, 124.1, 113.2, 68.3 (CH), 62.8 (CH), 
55.5 (CH3), 52.9 (CH3), 49.5 (CH), 30.6 (CH2); MS (EI): m/z 543 
(M++ H+, 19%), 542 (56), 484 (15), 483 (46), 411 (31), 337 (11), 
336 (12), 335 (11), 334 (14), 333 (12), 135 (100), 133 (13), 129 
(11), 107 (11), 89 (10), 77 (19); HRMS (DIP): m/z calculated for 
C30H26N2O6S: 542.1512, found: 542.1520.  
4.2.1.8. (2S,3S,4R,5S)-1-(5-(4-Methoxybenzoyl)-4-
phenylthiazol-2-yl)-4-nitro-3,5-diphenylpyrrolidine-2-carboxylic 
acid (5h’): Yellow oil (102.9 mg, 34% yield); [α]	 = -24.1 (c 
0.5, CDCl3, 99:1 er); IR υmax: 2959, 2945, 2926, 2852, 1740, 
1598, 1557, 1509 cm-1; 1H NMR (300 MHz, CDCl3) δ: 7.09-7.72 
(m, 17H, ArH), 6.55 (d, J = 8.9Hz, 2H, ArH), 5.90 (dd, J = 11.9, 
8.6 Hz, 1H), 5.72 (d, J = 9.3 Hz, 1H), 5.31 (d, J = 8.6 Hz, 1H), 
4.63 (dd, J = 11.9, 9.3 Hz, 1H), 3.72 (s, 3H, OCH3); 13C NMR 
(CDCl3) δ: 192.5 (C), 166.5 (C), 132.0 (ArC), 130.2, 129.9, 
129.4, 129.3, 129.2, 128.4, 128.1, 128.0, 127.8, 114.4, 113.9, 
113.6, 113.3, 113.2, 93.0 (CH), 66.8 (CH), 55.5 (CH3), 50.8 
(CH), 29.9 (CH); MS (EI): m/z 514 (M+ – CHNO4, 11%), 513 
(30), 512 (30), 235 (37), 193 (25), 191 (14), 135 (100), 115 (22), 
107 (11), 92 (12), 90 (12), 77 (28); HRMS (DIP): calculated for 
C33H26N2O2S [M+ – CHNO4], 514.1715 found, 514.1732.  
4.2.1.9. (5S,6R,7S)-5,7-difenil-6-nitro-3-tioxohexahidro-1H-
pirrolo[1,2-c]imidazol-1-one (8i): Yellow foam (194.5 mg, 
95%); [α] = -42.7 (c 1, CHCl3, 99:1 er); IR υ: 2954, 2925, 
1723, 1697, 1557, 1505 cm-1; 1H RMN (300 MHz, CDCl3) δH: 
7.05-7.44 (m, 10H, ArH), 5.86 (t, J = 10.7 Hz, 1H), 5.70 (d, J = 
9.5 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 3.17 (dd, J = 15.6, 4.1 Hz, 
1H), 2.19 (m, 1H), 2.19 (dd, J = 15.4, 4.6 Hz, 1H), 1.42 (d, J = 
6.7 Hz, 3H, CH3), 1.06 (d, J = 6.7 Hz, 3H, CH3); 13C RMN 
(CDCl3) δ: 178.3 (C), 162.6 (C), 135.8 (ArC), 133.2, 132.5, 
130.6, 129.6, 129.5, 129.3, 129.1, 128.8, 127.7, 92.4 (CH), 79.2 
(C), 72.7 (CH), 53.9 (CH), 52.5 (CH), 36.0 (CH2), 25.9 (CH3),; 
MS (EI): m/z 409 (M+-46, <2%), 366 (21), 276 (24), 194 (16), 
193 (100), 115 (32), 105 (63), 77 (26); HRMS (DIP): calculated 
for C19H16NOS [M+ –C3H7NO2], 367.1561, found, 367.1576. 
4.2.2. General procedure for the synthesis of pyrrolidines 
(6k,l,o). 
Method A: The solution of the corresponding dipolarophile (1 
mmol) in dry toluene (15 mL) was added to a stirred solution of 
the imine (1 mmol) in dry toluene (15 mL). The resulting mixture 
was stirred at reflux temperature for 32-48 h and purified by 
crystallization or column chromatography.  
Method B: To a stirred solution of imine (1 mmol) in dry toluene 
(15 ml) was added Et3N (0.23 mL, 1.7 mmol) and Ag2O (0.058 
mg 0.25 mmol). The reaction mixture was stirred for 10 minutes 
and the corresponding dipolarophile (1 mmol) in dry toluene (15 
mL) was added. The resulting mixture was stirred at room 
temperature for 26 h and quenched with saturated aqueous NaCl 
and NH4Cl, extracted with DCM, dried over MgSO4, and purified 
by column chromatography. 
 
4.2.2.1. Methyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-
yl)methyl]-3-(2,4-dichlorophenyl)-4,6-dioxo-5-
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phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6k): White 
solid (400 mg, 73 % yield); mp 311-313 ºC  (from 
EtOAc:hexane, decomp.); IR vmax: 3379, 2952, 1777, 1739, 
1713,1586 cm-1.  1H NMR (400 MHz, DMSO) δΗ: 10.25 (br.s, 
1H, NH), 7.80-7.02 (m, 13H, ArH), 5.42 (dd, J = 9.3 Hz, 4.60 
Hz, 1H), 4.19 (dd, J = 9.3 Hz, 7.73 Hz, 1H), 3.93 (dd, J = 7.7 Hz, 
1.4 Hz, 1H), 3.78 (s, 3H, OCH3), 3.73 (d, J = 14.4 Hz, 1H), 3.60 
(d, J = 14.7 Hz, 1H); 13C NMR (100 MHz, DMSO) δC: 174.9, 
173.5, 171.6 (CO), 136.3, 136.0, 134.1, 132.5, 132.0, 129.3, 
128.8, 128.2, 127.5, 126.9, 126.6, 124.4, 121.0, 118.5, 118.6, 
117.9, 111.5, 107.6, 70.3, 56.4, 53.2, 51.6, 46.7, 30.6. MS (EI): 
m/z (ESI): 548.1 (M+H+, 100), 549 (M+H+, 33). HRMS (DIP): 
calculated for (C29H23Cl2N3O4): 547.1076, found, 547.1070. 
4.2.2.2. Ethyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-yl)methyl]-
3-(4-chlorophenyl)-5-cyclohexyl-4,6-dioxo-
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6l): White solid 
(422 mg, 79 %); mp 245-247 ºC (from EtOAc:hexane); IR νmax: 
3353, 3058, 2932, 1761 cm-1; 1H NMR (400 MHz, CDCl3) δΗ: 
8.25 (br. s, 1H, NH), 7.56 (d, J = 7.8 Hz, 1H, ArH), 7.31-6.99 (m, 
8H, ArH), 4.84 (dd, J = 8.7 Hz, 2.2 Hz, 1H), 4.31-4.19 (m, 2H), 
3.81-3.72 (m, 1H), 3.61 (d, J = 14.6 Hz, 1H), 3.38 (d, J = 7.6 Hz, 
1H), 3.23 (d, J = 14.5 Hz, 1H), 2.46 (s, 1H, NH), 2.02-0.83 (m, 
11H), 1.33 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC: 
175.6, 174.6, 171.6 (CO), 136.3, 135.9, 133.8, 128.8, 128.4, 
127.8, 123.1, 122.3, 119.8, 118.2 111.4, 109.3, 71.1, 61.6, 60.6, 
53.7, 52.0, 48.8, 30.7, 28.9, 28.3, 25.7, 24.8, 14.1; MS (EI): m/z 
534 (M+H+, 100), 536 (M+H+, 35); HRMS (ESI): calculated for 
C30H33ClN3O4:   [MH]+ 534.2160, found 536.2153.  
4.2.2.3. Dimethyl (2R*,4S*,5R*)-2-[(1H-indol-3-yl)methyl]-5-
(4-chlorophenyl)pyrrolidine-2,4-dicarboxylate (6o): White solid 
(363 mg, 85%); mp 169-171 ºC (from EtOAc:hexane); IR vmax: 
3398, 3304, 2955, 2924, 1727, 1708 cm-1; 1H NMR (300 MHz, 
CDCl3) δΗ : 10.90 (s, 1H, NH), 7.52 (d, J = 7.9 Hz, 1H, ArH), 
7.34-6.94 (m, 8H,  ArH), 4.73 (t, J = 7.9 Hz, 1H), 3.59 (s, 3H, 
OCH3), 3.43 (dd, J = 15.6 Hz, 7.5 Hz, 1H), 3.20-3.08 (m, 6H), 
2.15 (dd, J = 13.3, 7.6 Hz,  1H); 13C NMR (75 MHz, DMSO) δC: 
175.1, 172.1 (CO), 140.3, 135.8, 131.4, 128.7, 127.8, 127.6, 
124.2, 120.7, 118.3, 111.3, 109.5, 69.6, 62.2, 51.7, 50.8, 48.5, 
36.1, 34.4; MS (ESI) m/z: 427 (M+H+, 100);  HRMS (ESI): 
calculated for C23H23ClN2O4:  426.1346, found 426.1343. 
 
4.2.3. General procedure for the synthesis of 
aminocarbothiol- pyrrolidines (7j-o). 
A solution of benzoyl isothiocyanate (0.213 mL, 1.3 mmol) in 
dry acetonitrile (15 mL) was added dropwise to a solution of the 
corresponding pyrrolidine (1.2 mmol) in dry acetonitrile (25 mL). 
The resulting solution was stirred at room temperature for 8-24 h. 
After completion of the reaction by monitoring TLC, the solvent 
removed and purified by flash chromatography. 
4.2.3.1. Methyl (1R*,3S*,3aR*,6aS*)-1-[(1H-indol-3-
yl)methyl]-2-(benzoylcarbamothioyl)-4,6-dioxo-3,5-diphenyl- 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (7j): Pale yellow 
solid (552 mg, 86%); mp: 164-166 ºC (diethyl ether); IR νmax: 
3344, 3251, 3063, 2952, 2848, 1787, 1720, 1596 cm-1; 1H NMR 
(400 MHz, CDCl3) δΗ: 11.32 (s, 1H, NH), 10.54 (s, 1H, NH), 
8.02 (s, 1H, ArH), 7.70 (d, J = 7.7 Hz, 1H, ArH), 7.50-7.05 (m, 
16H, ArH), 6.67-6.65 (m, 2H, ArH), 5.72 (d, J = 11.4 Hz, 1H), 
4.69 (d, J = 15.3 Hz, 1H), 3.91 (d, J = 9.4 Hz, 1H), 3.81-3.75 (m, 
4H), 2.91 (dd, J = 11.1 Hz, 9.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δC: 180.6 (CS), 173.4 (CO), 172.0 (CO), 168.0 (CO), 
164.8 (CO), 137.0,  136.8, 132.8, 132.1, 131.7, 128.6, 128.5, 
128.3, 128.2, 127.8, 127.8, 126.4, 125.8, 121.1, 119.1, 117.9, 
111.5, 106.8, 78.3, 68.7, 52.5, 52.1, 49.6, 27.1; MS (ESI) m/z: 
643.2 (M+ + 1, 100); HRMS (ESI-TOF-MS) calculated for 
C37H30N4O5S): 642.1937, found 642.1930. 
4.2.3.2. Methyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-
yl)methyl]-2-(benzoylcarbamothioyl)-3-(2,4-dichlorophenyl)-4,6-
dioxo-5-phenyl-octahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
(7k): Pale yellow prisms (605 mg, 85 %); mp 154-156 ºC (from 
EtOAc:hexane); IR (νmax): 3387, 2951, 2920, 2851, 1783, 1716, 
1593, 1559 cm-1;  1H NMR (400 MHz, CDCl3) δΗ : 8.48 (br. s, 
1H, NH), 8.18 (d, J = 8.3 Hz, 2H, ArH), 7.92 (d, J = 8.2 Hz, 1H 
ArH), 7.72 (d, J = 7.7 Hz, 1H), 7.62-7.06 (m, 12H, ArH), 6.57 (d, 
J = 7.3 Hz, 2H, ArH), 5.94 (d, J = 15.2 Hz, 1H), 4.45 (d, J = 15.0 
Hz, 1H), 4.01 (d, J = 15.2 Hz, 1H), 3.94-3.89 (m, 3H, ), 3.87 (s, 
3H, OCH3), 2.63 (dd, J = 10.4 Hz, 9.6 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δC: 181.4 (CS), 173.5, 171.8, 168.1, 164.1 (CO), 
138.8, 134.5, 133.8, 133.0, 132.5, 132.2, 131.7, 128.7, 128.7, 
128.6, 128.5, 128.3, 128.1, 128.0, 127.9, 126.4, 125.9, 121.2, 
119.2, 117.7, 111.6, 106.7, 78.9, 66.0, 52.4, 48.5, 26.8, 15.1. MS 
(ESI) m/z: 710.8 (M+-1, 100), 711.8 (40); HRMS (ESI): 
calculated for C37H28Cl2N4O5S: 711.1157, found 711.1167.  
4.2.3.3. Ethyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-yl)methyl]-
2-(benzoylcarbamothioyl)-3-(4-chlorophenyl)-5-cyclohexyl-4,6-
dioxo-octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (7l): Pale 
yellow prisms (558 mg, 80%); mp 148-150 ºC (from 
EtOAc:hexane); IR νmax: 3385, 2931, 1739, 1702 cm-1; 1H NMR 
(400 MHz, CDCl3) δΗ: 8.44 (br. s, 1H, NH, minor rotamer), 8.34 
(br. s, 1H, NH major rotamer), 8.10-7.03 (m, 30H, ArH, NH 
major and minor rotamer), 5.65 (d, J = 11.6 Hz, 1H, minor 
rotamer),  5.44 (d, J = 11.2 Hz, 1H, major rotamer), 4.79 (d, J = 
15.5, 1H,  minor rotamer), 4.43-4.21 (m, 4H, major and minor 
rotamer), 4.40 (d, J = 14.5, 1H,  major rotamer), 3.92 (d, J = 15.0 
Hz, 1H, major rotamer), 3.87 (d, J = 15.5, 1H,  minor rotamer), 
3.50-3.45 (m, 2H, major and minor rotamer), 2.74 (dd, J = 11.2, 
10.1 Hz, 1H, minor rotamer), 2.41 (dd, J = 11.2 Hz, 9.1 Hz, 1H, 
major rotamer), 1.86-0.81 (m, 22H, major and minor rotamer), 
1.47 (t, J = 7.08 Hz,  3H, major rotamer), 1.33 (t, J = 7.0 Hz, 3H, 
minor rotamer); 13C NMR (100 MHz, CDCl3) δC: 187.2 (CS 
major rotamer), 178.6 (CS minor rotamer), 174.1 (CO minor 
rotamer), 173.7 (CO major rotamer), 173.2 (CO major rotamer), 
173.0 (CO minor rotamer), 172.1 (CO major rotamer), 169.6 (CO 
major rotamer), 167.9 (CO minor rotamer), 163.8 (CO minor 
rotamer), 135.9 ( major rotamer), 135.8 (minor rotamer), 135.0 
(major rotamer), 134.7 (minor rotamer), 134.4 (minor rotamer), 
133.8 (major rotamer ), 133.5 (major rotamer), 133.1 (major 
rotamer), 133.0 (major rotamer), 132.3 (minor rotamer), 131.7 
(minor rotamer), 131.7 (minor rotamer),  129.2 (minor rotamer), 
128.7 (minor rotamer), 128.6 (major rotamer), 128.6 (minor 
rotamer), 128.2 (major rotamer),  127.8 (major rotamer), 127.6 
(major rotamer), 127.0 (minor rotamer), 125.8 (minor rotamer), 
124.3 (major rotamer), 122.7 (major rotamer), 122.3 (minor 
rotamer), 120.5 (major rotamer), 120.2 (minor rotamer), 118.0 
(minor rotamer), 117.9 (major rotamer), 111.8 (major rotamer), 
111.7 (minor rotamer), 108.7 (major rotamer), 108.2 (minor 
rotamer), 77.2 (minor rotamer), 76.0 (major rotamer), 68.9 
(minor rotamer), 68.2 (major rotamer), 66.9 (minor rotamer), 
62.4 (major rotamer), 53.9 (minor rotamer), 52.0 (major 
rotamer), 51.9 (major rotamer) 49.0 (minor rotamer), 47.4 (major 
rotamer), 32.9 (minor rotamer), 28.3 (major rotamer), 28.3 
(minor rotamer), 27.9 (minor rotamer), 27.7 (minor rotamer), 
27.5 (minor rotamer), 25.6 (minor rotamer), 25.5 (major 
rotamer), 24.7 (major rotamer), 14.0 (major rotamer); MS (ESI) 
m/z: 696 (M+ - 1, 100), 694 (35); HRMS (ESI-TOF-MS) 
calculated for C38H38ClN4O5S:  [MH]+  697.2251 (Cl:35), found 
697.2253 (Cl:35), 699.2269 (Cl:37).  
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4.2.3.4. Dimethyl (2R*,4S*,5R*)-1-
(benzoylcarbamothioyl)-2-benzyl-5-(2,4-
dichlorophenyl)pyrrolidine-2,4-dicarboxylate (7m):35 
4.2.3.5. Dimethyl (2R*,4S*,5R*)-1-(benzoylcarbamothioyl)-
5-(4-chlorophenyl)-2-phenylpyrrolidine-2,4-dicarboxylate (7n): 
Pale yellow prisms, (495 mg, 92%); m.p.: 162-165 ºC (from 
diethyl ether), 2:1 rotamer mixture; IR υmax: 3278, 3072, 2981, 
1953, 1743, 1675, 1596 cm-1; ;  1H NMR (400 MHz, CDCl3) δΗ: 
7.91-7.23(m, 30H, NH, ArH major and minor rotamers), 5.92 (d, 
J = 8.4 Hz, 1H, major rotamer), 5.89  (d, J = 8.4 Hz, 1H, minor 
rotamer), 3.92 (s, 3H, OCH3, major rotamer), 3.71 (s, 3H, OCH3, 
minor rotamer), 3.46-3.14 (m, 4H, major and minor rotamers), 
3.39 (s, 3H, OCH3, minor rotamer), 3.29 (s, 3H, OCH3, major 
rotamer), 2.72-2.54 (m, 2H, major and minor rotamers); 13C 
NMR (100 MHz, CDCl3) δC: 187.5 (CS, minor rotamer), 180.2 
(CS, major rotamer), 172.2 (CO, minor rotamer), 171.4 (CO, 
minor rotamer), 170.2 (CO, major rotamer), 169.0 (CO, minor 
rotamer), 168.7 (CO, major rotamer), 164.7 (CO, major rotamer), 
138.0, 135.6, 134.5, 134.4, 133.6, 133.3, 133,1, 132.8, 132.3, 
132.1, 129.3, 129.1, 129.1, 129.0, 128.8, 128.4, 128.4, 128.3, 
128.2, 128.1, 127.9, 127.7, 127.5, 127.3, 126.2, 125.4, 78.6, 75.5, 
67.0, 66.3, 53.4, 53.1, 51.8, 51.7, 57.1, 46.3, 41.2, 41.0. MS 
(ESI) m/z: 535.1 (M+-1, 100), 537.1 (35). Anal. Calc. for 
C28H25ClN2O5S: C, 62.62; H, 4.69; N, 5.22; S, 5.97. Found: C, 
62.89; H, 5.02; N, 5.00; S, 5.74. 
 
4.2.3.6. Dimethyl (2R*,4S*,5R*)-2-[(1H-indol-3-yl)methyl]-1-
(benzoylcarbamothioyl)-5-(4-chlorophenyl)pyrrolidine-2,4-
dicarboxylate (7o): Pale yellow prisms (472 mg, 80 %); mp 129-
131 ºC (from diethyl ether, decomp.); IR vmax: 3357, 2948, 2922, 
2850, 1731, 1559 cm-1; 1H NMR (300 MHz, CDCl3) δΗ: 8.38 (s, 
1H, NH major rotamer), 8.28 (s, 1H, NH minor rotamer), 8.17-
7.01 (m, 28H, ArH major and minor rotamer), 5.39 (d, J = 10.2 
Hz, 1H, major rotamer), 5.30 (d, J = 9.7 Hz, 1H minor rotamer),  
4.55 (d, J = 15.4 Hz, 1H major rotamer), 4.22 (d, J = 15.8 Hz, 
1H, minor rotamer), 3.94 (s, 3H, OCH3 major rotamer ), 3.81 (s, 
3H, OCH3 minor rotamer ), 3.77-3.68 (m, 2H, major and minor 
rotamer), 3.08 (s, 3H, OCH3 minor rotamer ), 3.00 (s, 3H, OCH3 
major rotamer
 
), 2.98-2.93 (m, 2H, major and minor rotamer), 
2.64-2.47 (m, 2H, major and minor rotamer); 2.45-2.40 (m, 2H, 
major and minor rotamer); 13C NMR (75 MHz, CDCl3)  δC: 
185.5 (CS, minor rotamer), 178.4 (CS, major rotamer),  173.5 
(CO, minor rotamer), 172.0 (CO, major rotamer), 169.6 (CO, 
minor rotamer), 169.3 (CO, major rotamer), 164.1 (CO, minor 
rotamer), 164.1 (CO, major rotamer),  136.0 (minor rotamer), 
135.8 (minor rotamer), 134.4 (minor rotamer), 133.5 (minor 
rotamer), 133.3 (minor rotamer), 133.0 (minor rotamer), 132.6 
(minor rotamer), 129.7 (minor rotamer), 129.1 (major rotamer), 
128.7 (major rotamer), 128.5 (minor rotamer), 128.0 (major 
rotamer), 127.6 (major rotamer), 125.4 (minor rotamer), 123.6 
(minor rotamer), 122.5 (minor rotamer), 122.1 (minor rotamer), 
120.3 (minor rotamer), 120.0 (minor rotamer), 118.3 (minor 
rotamer), 111.4 (major rotamer), 110.3 (minor rotamer), 109.5 
(minor rotamer), 73.7 (major rotamer), 71.2 (minor rotamer), 
68.0 (major rotamer), 67.5 (minor rotamer), 52.9 (minor 
rotamer), 51.4 (major rotamer), 47.2 (major rotamer), 45.7 
(minor rotamer), 37.2 (major rotamer), 36.4 (minor rotamer), 
31.2 (major rotamer), 26.4 (minor rotamer), 25.3 (minor 
rotamer), 22.6 (major rotamer); MS (ESI) m/z: 590 (M, 100), 
591 (39); HRMS (ESI): calculated for C31H28ClN3O5S: 
589.1438, found 589.1437. 
 
4.2.4. General procedure for the synthesis of pyrrolidine- 
thiazoles  (5j-o). 
2-Bromo-4′-methoxyacetophenone (320 mg, 1.4 mmol), 
dissolved in dry acetone (10 mL), was added dropwise to a 
solution of aminocarbothiolpyrrolidine (1 mmol) in dry acetone 
(10 mL), the resulting mixture was refluxed for 24–48 h 
(monitoring by TLC). The reaction was cooled down, the solvent 
evaporated, ethyl acetate was added (15 mL) and the resulting 
organic phase washed with bine, dried and evaporated. The crude 
product was purified by flash chromatography. 
4.2.4.1. Methyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-
yl)methyl)]-2-(5-(4-methoxybenzoyl)-4-phenylthiazol-2-yl)-4,6-
dioxo-3,5-diphenyl-octahydropyrrolo[3,4-c]pyrrole-1-
carboxylate  (5j): Yellow prisms (502 mg, 65 %); mp 148-150 ºC 
(diethyl ether, decomp.); IR νmax: 3439, 3057, 2954, 1785, 1734, 
1712, 1593 cm-1; 1H NMR (400 MHz, CDCl3) δH: 8.36 (s, 1H, 
NH), 7.85 (s,1H, ArH), 7.53-7.06 (m, 18H, ArH), 6.79 (s, 1H, 
ArH), 6.60-6.55 (m, 4H, ArH), 4.72 (d, J = 10.9 Hz, 1H), 4.66 (d, 
J = 15.1 Hz, 1H), 3.97 (s, 3H, OCH3), 3.94 (d, J = 8.9 Hz, 1H), 
3.77 (d, J = 15.2 Hz, 1H), 3.71 (s, 3H, OCH3), 2.82 (t, J = 9.9 Hz, 
1H); 13C NMR (75 MHz, CDCl3)  δC: 187.8 (CO), 173.2 (CO), 
172.3 (CO), 170.2, 165.2, 162.7,  155.9, 136.0, 134.8, 134.5, 
131.9, 130.9, 130.2, 130.1, 129.1, 128.9, 128.6, 127.7, 127.7, 
125.8, 124.6, 123.8, 122.8, 120.6, 117.9, 113.0, 111.9, 109.4, 
69.2, 55.3,54.5, 53.1, 49.8, 29.5;  MS (ESI) m/z: 773 (M+ + 1, 
100); HRMS (ESI): calculated for C46H36N4O6S: 772.2356, found 
772.2367. 
4.2.4.2. Methyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-
yl)methyl]-3-(2,4-dichlorophenyl)-2-(5-(4-methoxybenzoyl)-4-
phenyl-4,5-dihydrothiazol-2-yl)-4,6-dioxo-5-phenyl-
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (5k): Pale yellow 
prisms, (690 mg, 82 %); mp 166-168 ºC (diethyl ether, decomp.). 
IR νmax: 2951, 2922, 2851, 1788, 17.19, 1596, 1498 cm-1; 1H 
NMR (300 MHz, CDCl3) δH: 8.39 (s, 1H, NH), 7.92 (d, J = 8.4 
Hz, 1H, ArH), 7.58 (d, J = 8.0 Hz, 1H, ArH), 7.51 (d, J = 8.3 Hz, 
2H, ArH), 7.43 (d, J = 8.0 Hz, 1H, ArH), 7.37-7.08 (m, 12H, 
ArH), 6.78 (s, 1H, ArH), 6.71 (d, J = 7.3 Hz, 2H, ArH), 6.59 (d, J 
= 8.4 Hz, 2H, ArH), 5.23 (d, J = 10.8 Hz, 1H), 4.61 (d, J = 15.2 
Hz, 1H), 3.97 (m, 4H, OCH3), 3.78 (d, J = 15,2 Hz, 1H), 3.72 (s, 
3H, OCH3), 2.89 (t, J= 10.0 Hz, 1H); 13C NMR (75 MHz, CDCl3)  
δC: 187.6 (CO), 173.1 (CO), 171.6 (CO), 170.2 (CO), 164.6, 
162.9, 155.8, 136.0, 135.8, 135.6, 134.4, 132.0, 131.5, 130.0, 
129.1, 129.0, 128.7, 128.6, 127.9, 127.9, 127.7, 125.9, 125.4, 
123.8, 122.9, 120.7, 117.8, 113.1, 111.92, 109.8, 64.9, 55.3, 54.3, 
53.2, 48.7, 29.3; MS (ESI) m/z: 843 (M + 2, 100). HRMS (ESI): 
calculated for C46H34Cl2N4O6S): 841.7600, found 841.7610. 
4.2.4.3. Ethyl (1S*,3R*,3aS*,6aR*)-1-[(1H-indol-3-yl)methyl]-
3-(4-chlorophenyl)-5-cyclohexyl-2-(5-(4-methoxybenzoyl)-4-
phenylthiazol-2-yl)-4,6-dioxo-octahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (5l):): Pale yellow prisms (639 mg, 76 %); mp 161-
163 ºC (from diethyl ether); IR νmax: 3367, 2933, 2857, 1781, 
17.42, 1705, 1597, 1510 cm-1; 1H NMR (300 MHz, CDCl3) δH: 
8.46 (s, 1H, NH), 7.71 (d, J= 6.4 Hz, 1H, ArH), 7.49-7.04 (m, 
14H, ArH),  6.74 (s, 1H,  ArH), 6.58 (d, J = 8.6 Hz, 2H, ArH), 
4.57 (d, J = 15.1 Hz, 1H), 4.50 (d, J = 11.0 Hz, 1H), 4.44-4.38 
(m, 2H), 3.71 (m, 5H), 2.82 (t, J = 10.1 Hz, 1H), 1.84-0.86 (m, 
11H), 1.36 (t, J = 7.1 Hz,  3H);  13C NMR (75 MHz, CDCl3)  δC : 
187.8 (CO), 174.3 (CO), 173.3 (CO), 169.9 (CO), 165.0, 162.8, 
156.0, 136.1, 134.9, 134.4, 133.5, 132.0, 130.2, 130.1, 128.7, 
127.7, 124.5, 123.9, 122.6, 120.4, 118.0, 113.1, 111.8, 109.2, 
76.1, 68.2, 62.3, 55.4, 54.0, 52.1, 49.4, 29.5, 28.4, 27.9, 25.6, 
24.8, 14.2; MS (ESI) m/z: 827 (M, 100), 828 (55); HRMS (ESI): 
calculated for: C47H43ClN4O6S: 827.3930, found 827.3937. 
4.2.4.4. Dimethyl (2R*,4S*,5R*)-2-benzyl-5-(2,4-
dichlorophenyl)-1-(5-(4-methoxybenzoyl)-4-phenylthiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (5m): Pale yellow prisms (594 
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mg, 83 %); as: mp 115-117 ºC (from EtOAc:hexane, decomp.);  
IR νmax: 2951, 2920, 2839, 1739, 1595, 1511 cm-1; 1H NMR (400 
MHz, CDCl3) δH: 8.04 (d, J = 9.0 Hz, 1H, ArH), 7.47-7.04 (m, 
14H, ArH), 6.56 (d, J = 7.9 Hz, 2H, ArH), 5.11 (d, J = 9.7 Hz, 
1H), 4.27 (d, J = 14.2 Hz, 1H), 3.88 (s, 3H, OCH3), 3.71 (s, 3H, 
OCH3), 3.56 (d, J = 14.3 Hz, 1H), 3.18 (s, 3H, OCH3), 3.01 (t, J 
= 11.8 Hz, 1H), 2.40-2.30 (m, 2H). 13C NMR (75 MHz, CDCl3) 
δC: 190.0 (CO), 187.7 (CO), 173.6 (CO), 169.8, 164.7, 164.2, 
162.7, 156.6, 136.7, 131.9, 131.4, 130.6, 130.2, 130.1, 129.9, 
129.1, 128.5, 128.0, 127.8, 127.6, 114.1, 113.0, 73.0, 63.1, 53.1, 
51.7, 46.8, 38.0, 37.2, 30.8; MS (ESI) m/z: 715 (M, 100), 716 
(42); HRMS (ESI): calculated for C38H32Cl2N2O6S: 715.6420, 
found 715.6427. 
4.2.4.5. Dimethyl (2R*,4S*,5R*)-5-(4-chlorophenyl)-1-(5-(4-
methoxybenzoyl)-4-phenylthiazol-2-yl)-2-phenylpyrrolidine-2,4-
dicarboxylate (5n): Pale yellow prisms (467 mg, 70 %); mp 122-
124 ºC (diethyl ether); IR νmax: 2952, 2922, 2852, 1735, 1595, 
1572, 1509 cm-1; 1H NMR (400 MHz, CDCl3) δH: 7.67 (d, J= 8.0 
Hz, 2H, ArH), 7.43 (d, J = 8.0 Hz, 2H, ArH), 7.38-7.27 (m, 9H, 
ArH), 7.12-6.96 (m, 5H, ArH), 6.55 (d, J = 12.0 Hz, 2H, ArH), 
5.21 (d, J = 8.0 Hz, 1H), 3.82 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 
3.39 (d, J = 4.0 Hz, 2H), 3.33 (s, 3H, OCH3), 2.59-2.51 (m, 1H);  
13C NMR (75 MHz, CDCl3) δC : 187.5 (CO), 171.6 (CO), 169.1 
(CO), 165.2, 162.6, 156.3, 137.6, 134.8, 134.5, 134.3, 131.8, 130. 
3, 129.9, 129.8, 128.9, 128.3, 128.0, 127.7, 127.5, 127.4, 124.4, 
113.0, 75.0, 66.1, 55.3, 53.1, 51.7, 47.7, 41.7; MS (ESI) m/z: 667 
(M, 100), 668 (37). HRMS (ESI-TOF-MS): calcd. for 
C37H32ClN2O6S [MH]+ 667.1670; found 667.1688.  
4.2.4.6. Dimethyl (2R*,4S*,5R*)-2-((1H-indol-3-yl)methyl)-5-
(4-chlorophenyl)-1-(5-(4-methoxybenzoyl)-4-phenylthiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (5o): Pale yellow prisms (540 
mg, 75 %); mp 145-147 ºC (diethyl ether); IR νmax: 2952, 2921, 
2852, 1737, 1595, 1511 cm-1; 1H NMR (400 MHz, CDCl3) δH: 
8.32 (s, 1H, NH), 7.50-7.07 (m, 15H, ArH), 6.81 (d, J = 2.2 Hz, 
1H, ArH), 6.59-6.57 (m, 2H, ArH), 4.50 (d, J = 9.9 Hz, 1H), 4.35 
(d, J = 15.9 Hz, 1H), 3.92 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 
3.56 (d, J = 15.9 Hz, 1H), 3.08 (s, 3H, OCH3), 3.02 (t, J = 12.0 
Hz, 1H), 2.68-2.60 (m, 1H), 2.46 (dd, J = 12.9, 7.5 Hz, 1H);  13C 
NMR (75 MHz, CDCl3) δC: 187.7 (CO), 173.8 (CO), 169.6 (CO), 
165.2, 162.6, 156.5, 136.0, 134.8, 134.7, 134.4, 131.8, 130.5, 
130.0, 130.0, 128.5, 128.4, 128.0, 127.6, 123.9, 123.3, 122.4, 
120.1, 118.2, 113.0, 111.5, 100.7, 73.3, 67.8, 55.3, 52.9, 51.5, 
47.6, 37.4, 28.0; MS (ESI) m/z: 720 (M, 100); HRMS (ESI): 
calculated for C40H34ClN3O6S: 720.2371, found 720.2367. 
 
4.2.5. General procedure for the synthesis of pyrrolidine- 
thiazole  (9n-o). 
 2-Bromo-4′-methoxyacetophenone (320 mg, 1.4 mmol), 
dissolved in dry methanol (10 mL), was added dropwise to a 
solution of aminocarbothiolpyrrolidine (1 mmol) in dry methanol 
(10 mL), the resulting mixture was refluxed for 24–48 h 
(monitoring by TLC). The reaction was cooled down, the solvent 
evaporated, ethyl acetate was added (15 mL) and the resulting 
organic phase washed with bine, dried and evaporated. The crude 
product was purified by flash chromatography 
 
4.2.5.1. (2R*,4S*,5R*)-dimethyl 5-(4-chlorophenyl)-1-[4-(4-
methoxyphenyl)thiazol-2-yl]-2-phenylpyrrolidine-2,4-
dicarboxylate (9n): White solid (405 mg, 72 %); mp: 197-199 ºC 
(diethyl ether); IR νmax: IR νmax: 2952, 2920, 2855, 1737, 1591, 
1570, 1507 cm-1; 1H NMR (400 MHz, CDCl3)  δH: 7.65 (d, J = 
8.0 Hz, 2H, ArH), 7.53 (d, J = 4.0 Hz, 2H, ArH), 7.50-6.76 
(m,7H, ArH), 6.76 (d, J = 4.0 Hz, 2H, ArH), 6.52 (s, 1H), 5.18 
(d, J = 8.0 Hz, 1H), 3.86 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 3.36 
(d, J = 4.0 Hz, 2H), 3.32 (s, 3H, OCH3),  2.55-2.47 (m, 1H); 13C 
NMR (75 MHz, CDCl3) δC: 172.2 (CO), 169.5 (CO), 163.3, 
159.1, 151.1, 138.1, 135.5, 134.4, 129.7, 128.6, 127.8, 127.7, 
127.7, 127.2, 113.7, 100.4, 74.6, 65.6, 55.2, 53.0, 51.7, 47.8, 
41.4; MS (ESI) m/z: 563 (M, 100), 564 (33); HRMS (ESI-TOF-
MS): calcd. for C30H28ClN2O5S [MH]+ 563.1407; found 
563.1422. 
 
4.2.5.1. Dimethyl (2R*,4S*,5R*)-2-[(1H-indol-3-yl)methyl]-5-
(4-chlorophenyl)-1-(4-(4-methoxyphenyl)thiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (9o)): White prisms (499 mg, 
82%); mp 247-249 ºC (EtOAc:hexane, decomp.); IR νmax: 3371, 
2950, 2924, 2841, 1735, 1521 cm-1; 1H NMR (400 MHz, CDCl3) 
δH: 8.10 (s, 1H, NH), 7.76 (m, 2H, ArH), 7.48-6.89 (m, 10H, 
ArH), 6.77 (m, 1H, ArH), 6.58 (s, 1H), 4.46 (d, J= 9.9 Hz, 1H), 
4.41 (d, J= 15.0 Hz, 1H), 3.91 (s, 3H, OCH3), 3.82 (s, 3H, 
OCH3), 3.56 (d, J= 15.0 Hz, 1H), 3.08 (s, 3H, OCH3), 3.00 (t, J = 
12.7 Hz,  1H), 2.64 (dd, J = 19.7, 8.5 Hz,  1H), 2.42 (dd, J = 12.8 
Hz, 7.5 Hz, 1H);  13C NMR (75 MHz, CDCl3) δC: 174.5 (CO), 
169.9 (CO), 163.3 (CO), 159.2, 151.2, 136.1, 135.9, 134.0, 
129.9, 128.5, 128.2, 128.1, 127.9, 127.2, 123.3, 122.2, 120.0, 
118.6, 113.9, 111.2, 100.1, 72.9, 67.1, 55.3, 52.7, 51.4, 47.7, 
37.1, 27.4; MS (ESI) m/z:  616 (M+, 100), 617 (37). HRMS 
(ESI): calculated for C33H30ClN3O5S: 616.1290, found 616.1280. 
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Table 3. The MIC values (µg/mL) of the targed compounds against the bacteria and M. tuberculosis H37Rv strain. 
 
Compound Staphylococcus 
Aureus 
(ATCC 25925) 
Escherichia coli 
(ATCC 25923) 
Acinetobacter 
baumannii  
(ATCC 02026) 
Bacillus subtilis 
(ATCC 6633) 
Aeromonas 
Hydrophila 
(ATCC 95080) 
M. tuberculosis  
H37RV 
6m 500 µg/ml 250 µg/ml 125 µg/ml 250 µg/ml 500 µg/ml 62.5 µg/ml 
7m 250 µg/ml 250 µg/ml 125 µg/ml 125 µg/ml 125µg/ml 7.81 µg/ml 
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7n 250 µg/ml 250 µg/ml 125 µg/ml 62,5 µg/ml 125 µg/ml 31.25 µg/ml 
6j 250 µg/ml 125 µg/ml 62,5 µg/ml 125 µg/ml 125 µg/ml 20 µg/ml 
6l 250 µg/ml 250 µg/ml 125 µg/ml 250 µg/ml 500 µg/ml 31.25 µg/ml 
6o       250 µg/ml       250 µg/ml       125 µg/ml       250 µg/ml       250 µg/ml       1.95 µg/ml 
7k 250 µg/ml 500 µg/ml 125 µg/ml 125 µg/ml 250µg/ml 7.81 µg/ml 
7l 250 µg/ml 250 µg/ml 125 µg/ml 125 µg/ml 250 µg/ml 3.90 µg/ml 
7o 250 µg/ml 250 µg/ml 125 µg/ml 125 µg/ml 125 µg/ml 0.24 µg/ml 
5m 500 µg/ml 500 µg/ml 125 µg/ml 250 µg/ml 500 µg/ml 62.5 µg/ml 
9o 500 µg/ml 125 µg/ml 125 µg/ml 250 µg/ml 250 µg/ml 0.48 µg/ml 
5l 250 µg/ml 250 µg/ml 125 µg/ml 250 µg/ml 250 µg/ml 62.5 µg/ml 
Ampicillin 31.25 15.62 125 0.9 31.25  
Isoniazid      0.2 and 1 µg/ml 
Ethambuto
l 
     5 and 10 µg/ml 
MIC: Minimum Inhibitory Concentrations 
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